Method for isolating nucleic acids

Patent metadata

Field	Value
Publication number	US-10808276-B2
Application number	US-201715596275-A
Country	US
Kind code	B2
Filing date	May 16, 2017
Priority date	Aug 12, 2011
Publication date	Oct 20, 2020
Grant date	Oct 20, 2020

Abstract

It was found that adding a chelating agent during resuspension considerably increases the nucleic acid yield as the formation of precipitates which irreversibly adhere to the container wall is considerably reduced.

First claim

The invention claimed is:

1. A method for isolating nucleic acids from a sample, comprising:
a) obtaining a sample which has been stabilised by the use of at least one cationic detergent, wherein the cationic detergent has formed complexes with the nucleic acids;
b) obtaining the complexes optionally together with other sample components from the stabilised sample, wherein said complexes comprise the nucleic acids to be isolated;
c) generating a resuspended sample comprising
i) the nucleic acid to be isolated;
ii) at least one chaotropic agent;
iii) at least one chelating agent; and
iv) at least one non-chaotropic salt,

and
d) isolating nucleic acids from the resuspended sample,
wherein the isolated nucleic acids comprise RNA.

2. The method according to claim 1 , wherein the resuspended sample is put on hold between step c) and step d) for at least 0.2 h, at least 0.3 h, at least 0.4 h, at least 0.5 h, at least 0.75 h or at least 1 h and/or for a time period of 0.5 h to 12 h, 1 h to 10 h, 1.5 h to 8 h, 2 h to 7 h or 3 h to 6 h.

3. The method according to claim 1 , wherein the resuspension performed in step c) has one or more of the following characteristics:
a) a resuspension solution is added wherein said resuspension solution comprises the non-chaotropic salt;
b) the chelating agent is added before, during or after resuspension;
c) the chelating agent is added separately from the resuspension solution;
d) the chelating agent is comprised in a resuspension solution;
e) the chelating agent is added in a concentration so that the resuspended sample comprises the chelating agent in a concentration selected from 0.5 mM to 75 mM, 1 mM to 50 mM, 2.5 mM to 25 mM and 5 to 15 mM;
f) the chelating agent is selected from the group consisting of diethylenetriaminepentaacetic acid (DTPA), ethylenedinitrilotetraacetic acid (EDTA), ethylene glycol tetraacetic acid (EGTA) and N,N-bis(carboxymethyl)glycine (NTA) and/or
g) at least one additive is added before, during and/or after resuspension which is selected from the group consisting of chaotropic agents, protein-degrading compounds and buffering agents, and thereby is comprised in the resuspended sample.

4. The method according to claim 3 , wherein the resuspension performed in step c) has characteristic a), and wherein the non-chaotropic salt of characteristic a) is an ammonium salt.

5. The method according to claim 1 , wherein the chelating agent present in the resuspended sample
a) reduces binding of the precipitated sample to the container comprising the sample;
b) increases the yield of the isolated nucleic acid; and/or
c) reduces variations in the nucleic acid isolation efficiency or quantity attributable to different holding times between step c) and d).

6. The method according to claim 1 , wherein said method has with respect to the chaotropic agent comprised in the resuspended sample one or more of the following characteristics:
a) the concentration of the chaotropic agent in the resuspended sample is selected from the group consisting of 0.1 M to 4 M, 0.5M to 3M and 0.75M to 2.5M;
b) the concentration of the chaotropic agent in the resuspended sample is at least 1M;
c) the chaotropic agent is added in step c) in form of a separate solution;
d) the chaotropic agent is added in step c) after resuspension of the complexes and thereby is comprised in the resuspended sample;
e) the chaotropic agent present in step c) is selected from the group consisting of chaotropic salts, guanidinium hydrochloride, guanidinium thiocyanate (GTC), guanidinium isothiocyanate (GITC), sodium thiocyanate, sodium iodide, sodium perchlorate, sodium trichloroacetate, sodium trifluroacetate and urea; and/or
f) the chaotropic agent present in step c) is selected from GTC and GITC.

7. The method according to claim 1 , wherein step d) comprises binding the nucleic acids to a solid phase comprising silica.

8. The method according to claim 1 , wherein a protein degrading compound is added in step c).

9. The method according to claim 8 , wherein the protein degrading compound is a proteolytic enzyme optionally selected from the group consisting of proteinases, proteases, subtilisins and subtilases.

10. The method according to claim 9 , wherein the proteolytic enzyme is added before or during resuspension of the complexes.

11. The method according to claim 10 , wherein the proteolytic enzyme is proteinase K.

12. The method according to claim 1 , wherein step c) comprises:
aa) adding a resuspension solution that comprises a non-chaotropic salt and a chelating agent but no chaotropic agent, thereby resuspending the complexes,
bb) adding a chaotropic agent after resuspension of the complexes so that the chaotropic agent is comprised in the resuspended sample, and
cc) optionally adding a proteolytic enzyme before, during or after resuspension of the complexes and thereby is included in the resuspended sample.

13. The method according to claim 12 , wherein in step bb), the chaotropic agent is added to the resuspended complexes in form of an aqueous solution.

14. The method according to claim 1 , wherein the isolation performed in step d) comprises the following steps:
i) digesting and/or denaturing the resuspended sample, optionally by heating and/or agitating the resuspended sample in the presence of a proteolytic enzyme;
ii) binding the nucleic acids to a solid phase using appropriate binding conditions, and
iii) optionally washing the nucleic acids;
iv) optionally eluting the nucleic acids.

15. The method according to claim 1 , wherein the sample is a blood sample and in step a), the blood sample is stabilised by contacting the blood sample with a stabilizing composition comprising:
i) a cationic compound of the general formula:
Y + R 1 R 2 R 3 R 4 X −
wherein Y represents nitrogen or phosphor,
R 1 R 2 R 3 and R 4 independently, represent a branched or unbranched C 1 -C 20 -alkyl group, a C 6 -C 20 -aryl group and/or a C 6 -C 26 aralkyl group; and
X − represents an anion of an inorganic or organic, mono- or polybasic acid; and

ii) at least one proton donor.

16. The method according to claim 1 , wherein the sample is a blood sample, and in step a), the blood sample is stabilised by contacting the blood sample with a stabilizing composition comprising:
(i) an amino surfactant having the following formula (2):
R1R2R3N(O) x   (2)

wherein
R1 and R2 each independently is H, C1-C6 alkyl residue, C6-C12 aryl residue or C6-C12 aralkyl residue,
R3 is C1-C20 alkyl group, C6-C26 aryl residue, or C6-C26 aralkyl residue,
X is an integer of 0 and 1, and

(ii) an acid or acid salt.

17. The method according to claim 2 , wherein a plurality of samples is processed and wherein the holding time between step c) and step d) differs at least between some of the resuspended samples.

18. The method according to claim 1 , having one or more of the following characteristics:
a) a plurality of samples is prepared according to steps a) to c) thereby providing a plurality of resuspended samples, wherein the resuspended samples are divided into batches, and the nucleic acids are isolated from the batches according to step d), and wherein the holding time between step c) and d) varies at least between two batches;
b) step d) is performed using an automated system;
c) a plurality of samples is processed manually up to step c) thereby providing a plurality of resuspended samples, and wherein the resuspended samples are processed using an automated system for isolating the nucleic acids in ste

Assignees

• Qiagen Gmbh

Inventors

• Voss Thorsten

Classifications

• C12N15/1003

  Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor · CPC title

• C12Q1/6806 Primary

  Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence) · CPC title

• C12Q2527/127

  the enzyme inhibitor or activator used · CPC title

• C12Q2527/125

  Specific component of sample, medium or buffer · CPC title